The first therapy designed to prevent amyloid accumulation at every stage of disease — before plaques form, and long after antibody treatment.
“After almost a decade of cutting-edge translational research, we hold a potential therapy in our hands that goes beyond symptom management — targeting the root cause of Alzheimer’s by preventing amyloid accumulation before plaques can form, and sustaining that protection long after anti-amyloid antibody treatment.
Alzheimer’s therapy will have its iPhone moment!
”
Restoring the brain's endogenous protective pathway — a dual-benefit "two-for-one" mechanism
Founding team
partnering
